<DOC>
	<DOCNO>NCT02390219</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability LUM/IVA combination therapy subject 12 year old CF advance lung disease homozygous F508del CFTR mutation</brief_summary>
	<brief_title>Study Evaluate Lumacaftor Ivacaftor Combination Therapy Subjects 12 Years Older With Advanced Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Homozygous F508delCFTR mutation ; historical genotype must document participant 's source document . Percent predict FEV1 &lt; 40 adjust age , sex , height Screening Participant currently receive invasive mechanical ventilation . History comorbidity , opinion investigator , might confound result study pose additional risk administer study drug participant Any clinically significant laboratory abnormality screen would interfere study assessment pose undue risk subject A 12lead electrocardiogram ( ECG ) demonstrate QTcF &gt; 450 msec Screening History solid organ hematological transplantation History alcohol drug abuse past year Ongoing prior participation investigational drug study ( include study investigate lumacaftor and/or ivacaftor ) within 30 day screen . Use strong inhibitor , moderate inducer , strong inducer CYP3A Pregnant nursing female : Females childbearing potential must negative pregnancy test Screening Day 1 . Sexually active subject reproductive potential willing follow contraception requirement Use beta blocker equivalent Screening .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>